Abstract
Metastatic pancreatic cancer is one of the most aggressive cancer known in man yet specific anti-tumor immunity has been demonstrated in lymph nodes draining the sites of pancreatic tumors. Despite this immunity, pancreatic cancer patients suffer a quick demise. To further define tumor immunity in patients with metastatic pancreatic cancer, we sought to characterize helper T cell subsets, serum cytokines, cellular cytotoxicity that is both T-cell and non-T cell mediated, as well as known tumor-derived immunosuppressive products that may be present in their peripheral blood. Significantly heightened levels of interleukin 2 (IL-2), a Th1 cytokine, were found in patients before treatment with chemotherapy while serum IL-10, a Th2 cytokine, were at significantly lower levels than observed in normal donors tested between their fifth and seventh decades of life. IL-10 levels increased progressively with age as a serum-bound protein in normal, healthy donors tested between the ages of 24 through 61. An age associated progression of increased IL-10 levels was not observed in pancreatic cancer patients. Few patients had detectable serum levels of soluble fas ligand but approximately half had elevated levels of a tumor marker, detected with the CA-15.3 assay, known as soluble MUCIN 1 (MUC1). Cell mediated cytotoxicity including T-cell mediated killing of pancreatic tumor cell lines was detected in many patients. These data suggest that pancreatic cancer patients have activated type 1 helper T cells that can support development of cell-mediated immunity, and that their sera contain lowered levels of the “anti- inflammatory” type 2 cytokine, IL-10.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 5 March 1999 / Accepted: 21 May 1999
Rights and permissions
About this article
Cite this article
Plate, J., Shott, S. & Harris, J. Immunoregulation in pancreatic cancer patients. Cancer Immunol Immunother 48, 270–279 (1999). https://doi.org/10.1007/s002620050575
Issue Date:
DOI: https://doi.org/10.1007/s002620050575